Search results
Showing 331 to 345 of 1003 results for public health medicine & health
This guideline covers rehabilitation strategies for adults who have experienced a critical illness and stayed in critical care. It aims to improve physical, psychological and cognitive outcomes in people who have been discharged from critical care.
This quality standard covers prevention of falls and assessment after a fall in people who are living in the community, in a residential care setting or staying in hospital and are:
View quality statements for QS86Show all sections
Sections for QS86
- Quality statements
- Quality statement 1: Asking people about falls
- Quality statement 2: Comprehensive falls assessment
- Quality statement 3: Interventions to reduce the risk of falls
- Quality statement 4: Checks for injury after an inpatient fall
- Quality statement 5: Safe manual handling after an inpatient fall
- Quality statement 6: Medical examination after an inpatient fall
- Quality statement 7: Multifactorial risk assessment for older people presenting for medical attention
Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer [ID5113]
In development Reference number: GID-TA11025 Expected publication date: 10 February 2027
Awaiting development Reference number: GID-TA11673 Expected publication date: TBC
Awaiting development Reference number: GID-TA11507 Expected publication date: TBC
Dupilumab for treating eosinophilic oesophagitis in children 1 to 11 years [ID6492]
Awaiting development Reference number: GID-TA11383 Expected publication date: TBC
Awaiting development Reference number: GID-TA11608 Expected publication date: TBC
Xeomin (botulinum neurotoxin type A) for treating lower limb spasticity [TSID11902]
Awaiting development Reference number: GID-TA11417 Expected publication date: TBC
Awaiting development Reference number: GID-TA11748 Expected publication date: TBC
Awaiting development Reference number: GID-TA11754 Expected publication date: TBC
Elranatamab for treating relapsed or refractory multiple myeloma after 2 treatments [ID6464]
Awaiting development Reference number: GID-TA11661 Expected publication date: TBC
Benralizumab for treating hypereosinophilic syndrome in people 12 years and over [ID6322]
Awaiting development Reference number: GID-TA11360 Expected publication date: TBC
Awaiting development Reference number: GID-TA11594 Expected publication date: TBC
Awaiting development Reference number: GID-TA10972 Expected publication date: TBC
Awaiting development Reference number: GID-TA11632 Expected publication date: TBC